Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism

J Autism Dev Disord. 1995 Apr;25(2):183-93. doi: 10.1007/BF02178503.

Abstract

Treatment with 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP) has been suggested to improve autistic behavior. Cerebrospinal fluid (CSF) levels of total biopterin, oxidized and reduced forms of biopterin, homovanillic acid, and 5-hydroxyindoleacetic acid were measured in 14 autistic children and 18 controls to clarify the mechanism of action of R-THBP. The 14 autistic children received R-THBP orally at 1 mg/kg per day; 7 children showed clinical improvement (responders) and the other 7 patients did not (nonresponders). There were no significant differences between responders, nonresponders, and controls in the CSF levels of the metabolites before R-THBP administration. When lumbar puncture was repeated in 6 autistic children in the 24th week of R-THBP therapy, there was no significant change in the CSF levels of any metabolites.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autistic Disorder / cerebrospinal fluid
  • Autistic Disorder / drug therapy*
  • Biopterins / administration & dosage
  • Biopterins / adverse effects
  • Biopterins / analogs & derivatives*
  • Biopterins / cerebrospinal fluid*
  • Biopterins / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Homovanillic Acid / cerebrospinal fluid
  • Humans
  • Hydroxyindoleacetic Acid / cerebrospinal fluid
  • Male
  • Neurotransmitter Agents / cerebrospinal fluid*
  • Personality Assessment
  • Treatment Outcome

Substances

  • Neurotransmitter Agents
  • Biopterins
  • Hydroxyindoleacetic Acid
  • sapropterin
  • Homovanillic Acid